These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35535618)

  • 1. Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development.
    Li B; Qin X; Mi LZ
    Nanoscale; 2022 May; 14(19):7110-7122. PubMed ID: 35535618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NANOBODIES®: A Review of Diagnostic and Therapeutic Applications.
    Jin BK; Odongo S; Radwanska M; Magez S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application Progress of the Single Domain Antibody in Medicine.
    Tang H; Gao Y; Han J
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenobody: A Ferritin-Displayed Nanobody with High Apparent Affinity and Half-Life Extension.
    Fan K; Jiang B; Guan Z; He J; Yang D; Xie N; Nie G; Xie C; Yan X
    Anal Chem; 2018 May; 90(9):5671-5677. PubMed ID: 29634235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model.
    Li S; Meng X; Li R; Huang B; Wang X
    BMC Bioinformatics; 2024 Mar; 25(1):122. PubMed ID: 38515052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
    Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
    Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments.
    Arbabi-Ghahroudi M
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in nanobody and its application in diagnosis].
    Kong Q; Yao Y; Chen R; Lu S
    Sheng Wu Gong Cheng Xue Bao; 2014 Sep; 30(9):1351-61. PubMed ID: 25720150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobodies and their potential applications.
    Hassanzadeh-Ghassabeh G; Devoogdt N; De Pauw P; Vincke C; Muyldermans S
    Nanomedicine (Lond); 2013 Jun; 8(6):1013-26. PubMed ID: 23730699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.
    Liu B; Yang D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
    Hambach J; Mann AM; Bannas P; Koch-Nolte F
    Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a highly sensitive immunoassay based on pentameric nanobodies for carcinoembryonic antigen detection.
    Gu Y; Guo Y; Deng Y; Song H; Nian R; Liu W
    Anal Chim Acta; 2023 Oct; 1279():341840. PubMed ID: 37827654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NanoLAS: a comprehensive nanobody database with data integration, consolidation and application.
    Xiong S; Liu Z; Yi X; Liu K; Huang B; Wang X
    Database (Oxford); 2024 Jan; 2024():. PubMed ID: 38300518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Insights into the Design of Synthetic Nanobody Libraries.
    Valdés-Tresanco MS; Molina-Zapata A; Pose AG; Moreno E
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobody Conjugates for Targeted Cancer Therapy and Imaging.
    Kang W; Ding C; Zheng D; Ma X; Yi L; Tong X; Wu C; Xue C; Yu Y; Zhou Q
    Technol Cancer Res Treat; 2021; 20():15330338211010117. PubMed ID: 33929911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy.
    Piramoon M; Khodadust F; Hosseinimehr SJ
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188529. PubMed ID: 33647388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.